news
Using state-of-the-art gene editing technology, scientists have discovered a promising…
12 April 2017 | By Niamh Marriott (Drug Target Review)
Using state-of-the-art gene editing technology, scientists have discovered a promising target to treat atypical teratoid/rhabdoid tumour (AT/RT) - a highly aggressive and therapy resistant brain tumour that mostly occurs in infants.